Respiratory Today—April 17, 2026

LucidQuest

3 hours ago

This week’s Respiratory Research update highlights regulatory momentum, clinical trial progress, pipeline expansion, and increased competition in inhaled therapies.

In Today’s Newsletter

Dive deeper

🫁 AllRock starts Phase 2a ROC-101 in pulmonary hypertension [1] [US • 09 Apr 2026]

https://allrockbio.com/allrock-bio-doses-first-patients-in-phase-2a-trial-of-roc-101-for-pulmonary-hypertension/
Context: ROC-101 (AllRock Bio; oral pan-ROCK inhibitor) entered the open-label Phase 2a ROCSTAR study in PAH and ILD-PH, with up to 30 PAH and 10 ILD-PH patients.
Key point: AllRock Bio said first patients were dosed, including patients receiving ROC-101 with standard of care and a dedicated PAH arm on stable sotatercept.
Implication: May influence prescriber choice and payer reviews pending full data.

🌬️ Kymera adds asthma Fast Track for KT-621 [2] [US • 13 Apr 2026]

https://investors.kymeratx.com/news-releases/news-release-details/kymera-therapeutics-announces-us-fda-fast-track-designation-kt-0
Context: KT-621 (Kymera Therapeutics; oral STAT6 degrader) is in Phase 2b BREADTH in eosinophilic asthma and Phase 2b BROADEN2 in atopic dermatitis.
Key point: Kymera said the US FDA granted Fast Track designation to KT-621 for moderate to severe eosinophilic asthma.
Implication: May influence prescriber choice and payer reviews pending full data.

🧫 BioVersys and GSK publish AlpE mechanism data in TB [3] [EU • 13 Apr 2026]

https://ir.bioversys.com/news/data-published-in-nature-communications-highlights-unique-mechanism-of-action-of-alpibectir-in-combination-with/161aaf1b-2a21-40fc-b122-bc01c4c2002f
Context: AlpE (alpibectir plus ethionamide; BioVersys and GSK) was described as active in pre-clinical in vitro and in vivo TB models, and the release referenced ongoing pulmonary TB Phase 2b and TB meningitis Phase 2 studies.
Key point: BioVersys said Nature Communications published pre-clinical data supporting alpibectir’s mechanism in potentiating ethionamide and restoring susceptibility in resistant Mycobacterium tuberculosis strains.
Implication: Could inform practice and payer discussions; interpretation depends on study design and confounding control.

💨 Amneal launches first US respiratory MDIs [4] [US • 14 Apr 2026]

https://investors.amneal.com/news/press-releases/press-release-details/2026/Amneal-Launches-First-Two-Respiratory-Metered-Dose-Inhalation-Products-in-the-U-S-/default.aspx
Context: Amneal launched generic albuterol sulfate inhalation aerosol and beclomethasone dipropionate HFA inhalation aerosol, its first two US metered-dose inhalation products.
Key point: Amneal said the launches mark its entry into the complex inhalation category, with the products approved by FDA in 2025.
Implication: Introduces competition that may affect pricing and formulary access.

🧬 Savara gets three-month FDA review extension for molgramostim [5] [US • 15 Apr 2026]

https://investors.savarapharma.com/news/news-details/2026/Savara-Announces-the-U-S–Food–Drug-Administration-FDA-Has-Extended-the-Review-Period-for-the-Molgramostim-Inhalation-Solution-Molgramostim-Biologics-License-Application-BLA-in-Autoimmune-Pulmonary-Alveolar-Proteinosis-Autoimmune-PAP/default.aspx
Context: Molgramostim inhalation solution (Savara) is under Priority Review for autoimmune pulmonary alveolar proteinosis, or autoimmune PAP.
Key point: Savara said FDA extended the BLA review by three months after a major amendment, with a new PDUFA target action date of 22 Nov 2026; the company said FDA did not cite safety, efficacy, or manufacturing concerns.
Implication: May influence prescriber choice and payer reviews pending full data.

🤝 GSK closes 35Pharma acquisition, adds HS235 for pulmonary hypertension [6] [15 Apr 2026]

https://www.gsk.com/en-gb/media/press-releases/gsk-completes-acquisition-of-35pharma-inc/
Context: 35Pharma is a Canada-based clinical-stage company, and HS235 targets activin receptor signalling in pulmonary hypertension.
Key point: GSK said it completed the acquisition of 35Pharma for $950 million, adding HS235 and expecting proof-of-concept trials to start imminently in PAH and PH-HFpEF.
Implication: Signals pipeline investment and modality expansion.

Why it matters

Pulmonary hypertension is drawing fresh development activity across mechanisms, from AllRock Bio’s pan-ROCK inhibitor ROC-101 [1] to GSK’s activin-pathway asset HS235 [6].
Respiratory inflammation remains a priority area, with Kymera pushing an oral STAT6 degrader into a Fast Track-backed asthma program [2].
Tuberculosis pipeline activity is mixing translational science and clinical development, with BioVersys and GSK linking mechanism publication to ongoing mid-stage studies [3].
US inhalation-market competition may increase as Amneal expands from oral solids and injectables into respiratory MDIs [4].
Rare lung-disease timelines still matter commercially, and Savara’s molgramostim review extension resets a key regulatory milestone into late 2026 [5].

🚀 Accelerate your success. Contact us now

📂 Explore our case studies. See examples of our work.

💡 Read our insights. Learn from our latest reports and analysis

🧰 See our full range of services. Discover how we can help you.

📚 See the full Respiratory archive on our research hub page

🎯 Catch up on the Top Immunology news from the past two weeks, curated by the LucidQuest team.

🎬 Watch on YouTube.

FAQ

What is ROC-101 from AllRock Bio?

ROC-101 is an oral pan-ROCK inhibitor in Phase 2a development for pulmonary hypertension, including PAH and ILD-PH. AllRock said first patients have now been dosed in ROCSTAR, including in combination with standard of care such as sotatercept [1].

What did FDA Fast Track mean for Kymera’s KT-621 this week?

Kymera said KT-621 received US FDA Fast Track designation for moderate to severe eosinophilic asthma. The company also said Phase 2b asthma and atopic dermatitis studies are ongoing, with later readouts expected in 2027 [2].

Is AlpE already a late-stage TB drug?

Not yet. BioVersys said AlpE is supported by newly published pre-clinical mechanism data, while clinical work includes a pulmonary TB Phase 2b trial and a recently initiated TB meningitis Phase 2 trial [3].

Which inhalation products did Amneal launch?

Amneal launched albuterol sulfate inhalation aerosol and beclomethasone dipropionate HFA inhalation aerosol in the US. The company described them as its first two respiratory metered-dose inhalation product launches [4].

What changed for Savara’s molgramostim review?

Savara said FDA extended the BLA review by three months after classifying the company’s response to information requests as a major amendment. The new PDUFA target action date is 22 Nov 2026 [5].

Why does GSK’s 35Pharma deal matter?

GSK added HS235, a clinical-stage pulmonary hypertension candidate targeting activin receptor signalling. GSK said proof-of-concept trials are expected to begin imminently in PAH and PH-HFpEF [6].

Entities / Keywords

Pulmonary hypertension, PH, pulmonary arterial hypertension, PAH, ILD-PH, PH-HFpEF
AllRock Bio, ROC-101, ROCSTAR, pan-ROCK inhibitor, sotatercept
Kymera Therapeutics, KT-621, STAT6 degrader, eosinophilic asthma, atopic dermatitis, BREADTH, BROADEN2
BioVersys, GSK, alpibectir, ethionamide, AlpE, tuberculosis, TB meningitis, pulmonary TB, Mycobacterium tuberculosis
Amneal Pharmaceuticals, albuterol sulfate inhalation aerosol, beclomethasone dipropionate HFA, metered-dose inhaler, MDI
Savara, molgramostim inhalation solution, autoimmune PAP, pulmonary alveolar proteinosis, BLA, PDUFA
GSK, 35Pharma, HS235, activin receptor signalling